Anti--leucine-rich, glioma-inactivated 1 (LGI1) encephalitis is the second most frequent autoimmune encephalitis with an estimated annual incidence of 0.83 cases per million.^[@R1]^ Patients with LGI1 antibodies develop subacute onset of memory impairment, behavioral changes, and hyponatremia. The encephalitic phase is frequently preceded by a variable period where patients have isolated seizures including, among others, faciobrachial dystonic seizures.^[@R1],[@R2]^ Symptoms usually respond to corticosteroids, and nearly 70% of patients have good functional recovery. However, only a third of patients return to their baseline premorbid status.^[@R1],[@R3]^

Clinical assessment using only functional scales, such as the modified Rankin Scale (mRS) score, may overlook cognitive deficits that limit the return to previous activities and affect quality of life. However, studies that evaluate cognitive outcome in anti-LGI1 encephalitis are scarce and do not go beyond 2 years of follow-up. Previous research suggested that patients showed a marked impairment on memory, executive function, and processing speed at presentation, whereas some patients remained with residual deficits mainly observed on verbal memory.^[@R1],[@R4][@R5][@R7]^ In addition, the role of premorbid cognitive reserve that probably is relevant in the recovery of elderly patients after acute neurologic events has not been previously explored in cases of anti-LGI1 encephalitis.^[@R8]^

Telemedicine is a novel discipline that offers high-quality patient care through numerous applications and services that facilitate a direct, cost-effective exchange of information between patients and physicians.^[@R9]^ In the case of rare diseases or patients\' with restricted access to subspecialty care, such as autoimmune encephalitis, the use of telemedicine may be useful to assess cognitive performance in more detail over time.^[@R10]^

In this study, we assessed the feasibility of using a structured telephone interview to examine long-term cognitive performance and functional status of patients with anti-LGI1 encephalitis.

Methods {#s1}
=======

Patients {#s1-1}
--------

We reviewed all Spanish patients with anti-LGI1 encephalitis diagnosed at the Neuroimmunology laboratory of the Institut d\'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic (Barcelona, Spain), between September 1998 and June 2014. Patients were included if they fulfilled the following criteria: (1) age ≥18 years; (2) evidence of cognitive deterioration at diagnosis demonstrated by direct patient examination by one of the authors or provided by the referring physicians through a structured written questionnaire; and (3) minimum clinical follow-up of 4 years. We initially identified 49 patients, and 37 were finally included in the study. Reasons for exclusion were death (7 patients, 2 of them with dementia), severe dementia that precluded the telephone interview (3), and lost to follow-up (2). All 37 patients were invited by their referring physicians to participate in the study. After the patient\'s agreement to participate, one of the authors contacted the patient directly to explain the goals of the study and obtain informed verbal consent, witnessed by a relative. Appointments for the structured telephone interview were scheduled according to dates and times that were convenient for patients and relatives. Information on symptom onset and main syndromes, ancillary studies, treatment response to immunotherapy, and functional outcome at 24 months was previously reported.^[@R3]^

Telephone intervention characteristics {#s1-2}
--------------------------------------

Each telephone interview was performed by the same neurologist (N.S.) and lasted approximately 60 minutes. This included a structured interview with the patient about current clinical status, presence of comorbidities,^[@R11]^ the cognitive reserve questionnaire, and the Functional Activities Questionnaire (FAQ). Patients answered all the questions, and the answers were corroborated by a family member. The cognitive reserve questionnaire measured 8 different aspects of the premorbid intellectual activity (educational level and training courses, educational level of parents, work occupation performed throughout life, musical education, and ability to speak several languages) and cognitive-stimulating activities such as reading and practicing intellectual games ([table 1](#T1){ref-type="table"}). The final score was the sum of the scores for each item (maximum 25 points, best cognitive reserve).^[@R12]^ The FAQ is a standardized assessment of instrumental activities of daily living (11 items). Functional dependence is considered with scores ≥6 points.^[@R13],[@R14]^ Based on the aforementioned data, the mRS score was obtained, as this is the most widely used clinical outcome for measuring the degree of disability or dependence of patients with neurologic disability. The mRS is an ordered scale coded from 0 (no symptoms) through 5 (severe disability) and 6 (death). This scale has been shown to be reliable when obtained by telephone, and the Spanish version has been previously validated. Bad functional outcome was defined when the mRS score was ≥3.^[@R15],[@R16]^

###### 

Cognitive reserve questionnaire^[@R12]^
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Before starting the brief cognitive battery, the family member was asked to leave the room and remove any calendars, clocks, or devices that could interfere with the cognitive evaluation. The brief cognitive battery comprised the Spanish telephone version of the Mini-Mental State Examination (t-MMSE) and evaluation of 3 specific cognitive domains: verbal memory, executive function, and language. The Spanish version of the t-MMSE score ranges from 0 to 26, and cognitive impairment is defined when the score is ≤21 points.^[@R17],[@R18]^ Verbal memory was evaluated using the Free and Cued Selective Reminding Test modified from Buschke.^[@R19]^ Briefly, this test consists of one immediate recall task in which participants have to recall as many as 16 words (first free and then using a semantic clue) and a delayed recall task after 30 minutes. Only the delayed recall score (the sum of free and facilitated) was used for the memory index, as this score was highly correlated with the immediate recall score in our study population (list recall: rho = 0.84, *p* \< 0.001). Executive function was assessed using the oral Trial Making Test A and B.^[@R20],[@R21]^ In this test, participants are asked to count from 1 to 25 as quickly as possible (part A) and count again, but switching between numbers and alphabet letters until 13 (part B). The final score is the time in seconds needed to complete task B. Language was explored evaluating the verbal fluency asking the participants to say as many words as possible in 1 minute from a semantic category (e.g., fruits and vegetables), and the final score was the total number of words provided.

The brief cognitive battery was initially tested in a group of 23 healthy controls to ensure the feasibility to perform it by telephone and to obtain reference values for the cognitive tests. Controls had a median age of 74 years (interquartile range \[IQR\], 64--80) and 9 (39%) were male. No significant difference was observed in demographic variables or educational level between patients and healthy controls. To compare the cognitive performance across patients, raw scores from individual tests were converted to z-scores. Mild cognitive impairment (MCI) was considered when one or more cognitive domains showed a z-score below −1.5 SD of the healthy controls\' distribution without interference in the activities of daily living.^[@R22]^ Dementia was considered when these cognitive changes had a negative impact on the activities of daily living.

At the end of the telephone interview, all participants were assessed by the Hospital Anxiety and Depression Scale (score ≥11 points identified patients with mood disturbances) and the Pittsburgh Sleep Quality Index questionnaire (a score ≥6 points was indicative of poor quality of sleep).^[@R23],[@R24]^ Participants were also verbally assessed with the five-level version of the EuroQoL-5 dimensions instrument, which measures health-related quality of life. This instrument comprises the European quality (EQ) index value divided into 5 dimensions (mobility, self-care, usual activities, pain/complaints, and anxiety/depression) and the visual analog score (EQ-VAS).^[@R25]^

Standard protocol approvals, registrations, and patient consents {#s1-3}
----------------------------------------------------------------

The ethics committees of the Hospital Clinic approved the study. All patients or proxies gave written informed consent for the storage and use of serum, CSF, and clinical information for research purposes. All patients and healthy controls gave consent to participate in the telephone interview.

Statistics {#s1-4}
----------

Descriptive statistics were computed as median (IQR) unless otherwise noted. Differences among groups based on cognitive performance were studied using the χ^2^ test and Mann-Whitney *U* test as convenient, with a significance level set to *p* \< 0.05). Binary logistic regression was performed to identify predictors of cognitive impairment (MCI and dementia). Accuracy of the potential predictive value of clinical variables to detect patients with cognitive impairment was analyzed by the area under the curve (AUC). Statistical analyses were performed using SPSS version 25.0 (SPSS Inc, Chicago, IL) software.

Data availability {#s1-5}
-----------------

Data from the patients reported within the article are available and will be shared anonymously by request from any qualified investigator.

Results {#s2}
=======

Feasibility of telephone intervention and demographic characteristics {#s2-1}
---------------------------------------------------------------------

The telephone interview was successful in 36/37 (97%) patients. Only one patient complained about the length of the interview before starting the brief telephone cognitive battery and did not agree to continue. Clinical and demographic features of the 36 patients are summarized in [table 2](#T2){ref-type="table"}. The median age at diagnosis was 65 years (IQR: 56--74 years), and 23 (64%) were male. At the time of diagnosis of anti-LGI1 encephalitis, patients had a median mRS score of 4 (IQR: 3--4). All patients were treated with first-line immunotherapy (steroids ± IV immunoglobulin), and 18 (50%) also received second-line (11) or chronic (7) immunotherapy. At 2 years, 28 (78%) were functionally independent (mRS score \<3). At the last visit, 12 (33%) patients were still on antiepileptic drugs, but only 3 patients (8%) had experienced seizures during the preceding year.

###### 

Demographic and clinical description of 36 patients with anti-LGI1 encephalitis who completed the telephone interview
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Long-term cognitive and functional status {#s2-2}
-----------------------------------------

Long-term evaluation of patients was analyzed after a median follow-up of 87 months (IQR: 63--136 months). Patients performed significantly worse in all cognitive tests compared with healthy controls ([table 3](#T3){ref-type="table"}), and 27/36 (75%) were considered to have cognitive impairment that was classified as MCI in 17 (63%) and dementia in 10 (37%). The t-MMSE and the assessment of specific cognitive domains showed moderate agreement in the detection of cognitive impairment (kappa coefficient = 0.54; 95% CI: 0.30--0.78; *p* \< 0.001). Nineteen of the 36 (53%) patients were considered cognitive impaired using t-MMSE and the assessment of specific cognitive domains, and 8 (29%) of 27 patients were classified as MCI by the brief cognitive battery despite performing well on the t-MMSE. In contrast, none of the patients who performed well in the cognitive evaluation had a low score in the t-MMSE. Patients with dementia showed worse results in executive functioning and verbal fluency compared with patients with MCI (*p* \< 0.001 in both domains) ([figure](#F1){ref-type="fig"}). Overall, the most frequently affected cognitive domain was verbal fluency (N = 19, 53%), followed by verbal memory (N = 18, 50%) and executive functioning (N = 11, 31%).

###### 

Results of the brief cognitive battery and related assessments obtained by telephone interview
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Patients showed higher degrees of anxiety and/or depression and worse sleep quality than healthy controls ([table 2](#T2){ref-type="table"}). Six (17%) patients had symptoms of emotional distress, and 14 (39%) referred to poor quality of sleep. Quality of life perceived by the patients was not different from that of controls with the exception of the 10 patients with dementia (median EQ-VAS score: 69% vs 80% of controls; *p* = 0.03).

Twenty-six of the 36 patients (72%) were considered functionally independent (FAQ \< 6 points). Eleven of them (42.3%) were functionally normal (mRS score = 0), 4 (15.4%) had symptoms without significant disability (mRS score = 1), and 11 (42.3%) were independent but unable to perform premorbid activities (mRS score = 2). Despite the good functional status, 17/26 (65%) patients had evidence of MCI. The remaining 10 (28%) patients were functionally dependent (FAQ ≥ 6) with an mRS score ≥3, and all had dementia.

Predictors of long-term cognitive outcome {#s2-3}
-----------------------------------------

Compared with cognitively normal patients, the estimated premorbid cognitive reserve of the 27 patients with cognitive impairment was lower (median \[IQR\]: 9 \[7--13\] vs 16 \[9--17\] points; *p* = 0.02), more frequent bilateral hippocampal hyperintensity on initial MRI (67% vs 11%; *p* = 0.009), poor response to first-line treatment (52% vs 11%; *p* = 0.03), required second-line treatment (41% vs 0%; *p* = 0.02), and had worse an mRS score at 2 years (mRS score ≥3 = 70% vs 33%; *p* = 0.049). No differences were observed regarding age at diagnosis, the presence of distinct clinical or paraclinical features, the delay to first-line treatment, the occurrence of relapses, or the time of follow-up. In the logistic regression analysis, including age, time of follow-up, and the existence of comorbidities as covariates, the estimated premorbid cognitive reserve (OR = 1.36, 95% CI: 1.05--1.76, *p* = 0.02) and the presence of bilateral hippocampal hyperintensity at the initial MRI (OR = 27.03, 95% CI: 1.87--390, *p* = 0.02) were independent predictors for long-term cognitive impairment. In fact, an estimated premorbid cognitive reserve cutoff point of 14.5 points was able to discriminate patients who developed cognitive impairment from those who did not (sensitivity 0.67, specificity 0.89, and accuracy AUC = 0.75, 95% CI = 0.53--0.98, *p* = 0.03).

Discussion {#s3}
==========

This study shows the advantages and feasibility of using a structured telephone interview to assess the cognitive and functional status of patients who had anti-LGI1 encephalitis. Our findings show that the outcome evaluation of autoimmune encephalitis only based on the mRS score is not optimal and often misses the detection of cognitive deficits. Concerning the long-term outcome of patients with anti-LGI encephalitis, we found that 75% had cognitive deficits, ranging from MCI to dementia, and that the estimated premorbid cognitive reserve and presence of bilateral MRI hippocampal hyperintensity at disease onset are independent predictors for long-term cognitive impairment.

The use of our structured telephone intervention provides more reliable information than that obtained only assessing the functional status according to the impression of patients\' physicians or relatives, and it is particularly useful for patients with rare diseases who often come from distant geographical locations or patients whose clinical status limits follow-up visits.^[@R9]^ The observed moderate agreement between the t-MMSE and the cognitive battery of tests suggests that it is worth including the t-MMSE in the routine outcome assessment of autoimmune encephalitis, although it does not capture all cases with MCI (29% missed in this study). Adding the indicated cognitive battery of tests increases the length of the interview but provides relevant information on distinct cognitive functions, which may potentially be affected differently depending on the type of autoimmune encephalitis.^[@R26]^

As far as the evaluation of the functional status is concerned, the inclusion of the FAQ helps to confirm the mRS score. The FAQ is focused on the ability to perform the activities of daily living (e.g., preparing meals or managing personal finances) that are affected at early stages of dementia development, probably before the mRS score is affected.^[@R27]^ Other comorbidities could affect the mRS score but not specific items of FAQ. In our study, 72% of patients had a good functional status (mRS score \<3) after a median follow-up of 7 years. This [figure](#F1){ref-type="fig"} would decrease to 67% if we include the 3 patients with severe dementia that could not carry out the interview. In any case, the frequency is similar to that reported in a Dutch series (67%)^[@R1]^ and our own series (71%)^[@R3]^ in which the follow-up was 2 years.

Among the 26 patients who were functionally independent, only 9 (35%) had normal cognitive function emphasizing the need to include a formal cognitive evaluation to assess the full effect of anti-LGI1 encephalitis in patients\' outcome. We detected lower scores in cognitive domains beyond memory deficits.^[@R5]^ A similar result, including visuospatial memory deficits, was identified in a series of 30 patients examined a median of 2 years after onset of anti-LGI1 encephalitis.^[@R4]^ Another series consisting of 11 patients with a good mRS score (0--2) who had neuropsychological assessment after a median of 44 months from disease onset showed that visuospatial recognition memory was the main residual deficit.^[@R1]^ This cognitive domain could not be assessed in our telephone interview, suggesting that the frequency of cognitive impairment could be even higher than that reported here.

Our study shows that a lower estimated premorbid cognitive reserve and the presence of bilateral MRI hippocampal hyperintensity at disease onset are 2 independent predictors of long-lasting cognitive impairment. Cognitive reserve is defined as the adaptability of cognitive processes to brain aging, pathology, or insult. It is influenced by innate individual differences and the exposure to different socio-occupational factors such as early life education, profession, leisure activities, and/or social engagement.^[@R28],[@R29]^ Among several different approaches to assess cognitive reserve, we used a questionnaire that assesses a limited number of intellectual activities to ease the telephone interview, but the activities selected are among the most important.^[@R12]^ High cognitive reserve has been found associated with a reduced rate of cognitive decline and dementia.^[@R30]^ Prospective longitudinal studies of patients who developed mild cognitive impairment or Alzheimer showed that a higher premorbid cognitive reserve delayed the onset of cognitive decline, although this decline accelerated as soon as the symptoms of dementia started.^[@R31]^ A high educational level, the most commonly assessed cognitive reserve indicator, has been associated with a reduced risk of postoperative cognitive dysfunction or better cognitive outcome after traumatic brain injury.^[@R32],[@R33]^ Therefore, it is likely that a high cognitive reserve also influences the outcome in patients with anti-LGI1 encephalitis.

The cognitive deficits of patients with anti-LGI1 encephalitis have been found associated with the presence of residual structural damage to the hippocampus as evaluated by MRI.^[@R4]^ We postulate that patients with bilateral hippocampal MRI abnormalities at disease onset probably have more brain inflammation than those with unilateral lesions or normal MRI and are at risk to eventually develop more severe hippocampal atrophy explaining the association we found with poor cognitive outcome.

Our study has several limitations. First, we used a transversal design that prevents ascertaining if the long-term cognitive changes result from the acute stage of the encephalitis or from a prolonged, albeit mild, inflammatory activity that contributes to irreversible deficits. Moreover, considering the median age of patients with anti-LGI1 encephalitis, the worsening cognitive status over time of some patients could potentially have been influenced by unrelated comorbidities (e.g., neurodegenerative processes) that were unmasked or aggravated by the autoimmune inflammatory changes. Telephone assessment could only be performed to patients with good familiar support and accessible by phone, which may limit the assessment of institutionalized patients or with advanced dementia downplaying the real impact of anti-LGI1 encephalitis in the cognitive status. Last, we could only explore the cognitive reserve by partially assessing various aspects of life experience but the concept of reserve also accounts for individual differences in susceptibility to age-related brain changes that could not be assessed in this study.^[@R28]^

A comprehensive evaluation of the long-term outcome of patients with anti-LGI1 encephalitis is essential for a better knowledge of the cognitive domains predominantly affected by the disease and optimal assessment of the efficacy of immunotherapies. We have demonstrated that telemedicine through a structured telephone interview is feasible and provides a good instrument to address these issues. Future studies are encouraged to confirm these results and to validate the brief cognitive battery for its standard use in the evaluation of anti-LGI1 and other autoimmune encephalitis, and it should be considered, along with the mRS, for the long-term assessment of autoimmune encephalitides.
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